Thus, the present study revealed that, in bladder cancer, NF-κB can maintain its activity by establishing a feedback loop, in which NF-κB induced the expression of miR-130b, which consequently inhibited the expression of CYLD, which in turn was an endogenous inhibitor of NF-κB activation. The gene discussed is NFKB1; the disease is urinary bladder cancer.